PRIMETIME
Post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers
This study is to see if women who only have a very small risk of their breast cancer returning need to have radiotherapy after surgery.
Radiotherapy reduces the risk of the cancer coming back in the breast (local recurrence). But radiotherapy has side effects. For women who only have a very small chance of their cancer coming back, the side effects of radiotherapy could outweigh the benefits.
In this study researchers do an extra test on the sample already taken from a biopsy This is called a Ki67 test. The result of the Ki67 test is used with other routine test results and information about the type of breast cancer. From this the researchers can create a score which can show who might be at a:
- low risk of their cancer coming back
- very low risk of their cancer coming back
This score is called the IHC4+C score.
The study aims to find out:
- which women are at very low risk of their breast cancer coming back
- if these women can avoid having radiotherapy treatment
Further details at - CRUK or Association of Breast Surgery
News
ICPV Review 2018
We have at last published a new edition of our review. This was achieved by a grant from Novartis. Click here for more
information.
Award for ICPV Member
Many congratulations to ICPV member Margaret Grayson. On 21 April 2018 she received the Iris Colvin Lifetime Achievement Award for Health, presented by the Women’s Forum of Northern Ireland. This is very well deserved for her tireless work in furthering cancer research especially in Northern Ireland.
Warwick Clinical Trials
Course
12 members of ICPV attended a residential
Clinical Trials Course at the University of Warwick from 17th to 19th April 2018. The course was run by Professor Janet Dunn and covered the different types of studies undertaken; consent; trial
design; statistics and bringing a drug to market. One of the highlights of the course was a visit to the West Midlands Surgical Training Centre where delegates had the privilege of seeing real body
parts and having basic anatomy explained to them by the team. The delegates would like to thank Professor Janet Dunn for her outstanding enthusiasm and for her generous
hospitality.
Open letter calling on Government to prioritise interests of cancer patients in Brexit negotiations
ICPV have come together with 18 other cancer charities to put our names to an open letter to Government. We want Government to prioritise seeking continued alignment with the EU drug licensing
process and Clinical Trials Regulation after Brexit. It is hoped this letter will be published in the national press in the near future.
See below to read.
2017 Summer School
The 2017 ICPV Summer School was held over two days in June at Stirling University. The theme of the event was Cancer Survivorship and Living Well Cancer. Click below for details of the course. More details.
VOICE 2016
A snapsot video of the the 2016 course is now available on YouTube VOICE2016
eCancer Videos
At the BACR/ECMC conference in July Maggie Wilcox and Mairead Mackenzie were persuaded to speak to the camera. Maggie gave a background to ICPV and our aims and objectives. While Mairead focused on her specific interests and activities. To view follow the links below.
July 2016 Conferences
ICPV members were busy this week with two conferences. The BACR/ECMC Joint Meeting on Therapeutic Interventions for Cancer Prevention was held in Bristol July18-19. The UK Breast Cancer Research Symposium was held in London from July 22-23. Click here for more information.
UK Therapeutic Cancer Prevention Network (UKTCPN)
An update from this new group was presented to the ECMC Annual Network Meeting in May 2016. Click here to download and read.
UNITE2CURE
Call for immediate change to European Paediatric Medicine Regulation to save more lives of children and teens with cancer.
A few basic changes to European Law could speed up access to newer, kinder and potentially better drugs for more children and teenagers with cancer. Click to Sign the petition
TRACERx
Two years on from the start pioneering TRACERx lung cancer study. Click here For the latest news and patient views on this study.
Print 